Skip to main content
MedPathMedPath Home
Clinical Trials/PER-019-04
PER-019-04
Completed
未知

STUDY PHASE IV RANDOMIZED, OPEN, MULTICENTER, TO EVALUATE THE ANTIVIRAL EFFICACY AND SAFETY OF ATAZANAVIR WITH AND WITHOUT RITONAVIR IN COMBINATION WITH LAMIVUDINE AND STADUVINA OF PROLONGED RELEASE IN VIRGIN PATIENTS OF ANTIRETROVIRAL TREATMENT

BRISTOL MYERS SQUIBB COMPANY,0 sites0 target enrollmentMay 5, 2004
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions-B24 Unspecified human immunodeficiency virus [HIV] diseaseUnspecified human immunodeficiency virus [HIV] diseaseB24

Overview

Phase
未知
Intervention
Not specified
Conditions
-B24 Unspecified human immunodeficiency virus [HIV] disease
Sponsor
BRISTOL MYERS SQUIBB COMPANY,
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 5, 2004
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Signed Informed Consent
  • •HIV RNA greater than or equal 200 copies/mL at screening
  • •18 years old or older
  • •Must use barrier contraception
  • •Women of child\-bearing potential must have a negative serum or urine pregnancy test within 72 hours before beginning to take the study medications

Exclusion Criteria

  • •Unable or unwilling to use acceptable method of birth control for the entire study period including 8 weeks after the study
  • •Women using oral contraceptives, pregnant or breastfeeding women
  • •Women who have a positive pregnancy test on enrollment or before beginning to take the study medications
  • •People who have a life expectancy of greater than 12 months
  • •Newly diagnosed HIV\-related OI or any medical condition requiring acute therapy at the time of enrollment
  • •Any antiretroviral therapy within 30 days prior to screening

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Open, multicenter and randomized study phase IV to evaluate the efficacy and safety of 24 weeks more of treatment in patients with chronic hepatitis C genotype 1 and/or 4 co-infected with human inmmunodeficiency virus - Treatment of co-infected HIV/HCV patients genotype 1/4 24 weeks more than standar duratioChronic hepatitis C
EUCTR2004-004948-45-ESJosé Hernández-Quero. Hospital Clínico San Cecilio
Active, not recruiting
Not Applicable
24 weeks vs. 48 weeks of treatment of coinfected HIV/HCV patients genotype II-IIIHepatitis CTherapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2005-000203-34-ESEnrique Ortega González186
Active, not recruiting
Phase 1
Estudio de fase IV, multicéntrico, aleatorizado y doble ciego para comparar la seguridad y eficacia de 180 µg de Pegasys® más 1000 ó 1200 mg de Copegus® con la combinación actualmente aprobada de 180 µg de Pegasys® más 800 mg de Copegus® en pacientes con infección por el virus de la hepatitis C crónica del genotipo 1 coinfectados con el virus de la inmunodeficiencia humana (VIH-1), que no hayan sido previamente tratados con interferón.
EUCTR2005-005506-23-ESF. Hoffmann-La Roche Ltd400
Completed
Not Applicable
RANDOMIZED, MULTICENTER, OPEN, PHASE III,STUDY OF LAPATINIB, TRASTUZUMAB AND ITS COMBINATION IN NEOADYUVANCIA MORE PACLITAXEL IN WOMEN WITH PRIMARY BREAST CANCER HER2 / ERBB2 POSITIVE-C509 Breast, unspecifiedBreast, unspecifiedC509
PER-089-07OVARTIS BIOSCIENSES PERU S.A.,38
Active, not recruiting
Not Applicable
Phase IV, multicenter, open label, randomized study of Rebif® 44 mcg administered three times per week by subcutaneous injection compared with no treatment in the therapy of relapsing multiple sclerosis after mitoxantrone - Deescalation to Rebif® after Mitoxantrone therapy (REMAIN study)
EUCTR2005-001026-89-DESerono GmbH100